The report provides a detailed analysis essential for establishing a Gadoteridol production plant. It encompasses all critical aspects necessary for Gadoteridol production, including the cost of Gadoteridol production, Gadoteridol plant cost, Gadoteridol production costs, and the overall Gadoteridol production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Gadoteridol production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Gadoteridol is mainly used as a contrast agent to improve MRI scans. It helps doctors see soft tissues, blood vessels, and internal structures more clearly, which makes it easier to identify medical conditions. It is also used for scans of other organs when clearer imaging is needed to support diagnosis and treatment decisions. It finds its application in hospitals during complex evaluations where normal MRI images may not show enough detail. It is often used in research studies that focus on improving imaging techniques or comparing different contrast materials.
The demand for Gadoteridol is primarily driven by its application as a preferred medical contrast agent for many diagnostic procedures, including MRI scans, which greatly promotes its market expansion. Its usage in hospitals and imaging centres to ensure safe and effective scanning further strengthens its demand in the medical and diagnostics industries. Its application in detecting brain and spinal disorders, along with the growing need for accurate imaging in cancer and neurological cases, also strengthens its demand in the medical imaging industry. Rising investment in advanced MRI systems and the expansion of imaging services in both public and private healthcare facilities further add to its market growth. Procurement decisions for industrial Gadoteridol procurement are shaped by factors like the cost and steady supply of raw materials, strict regulatory standards for patient safety, and compliance with environmental rules. Improvements in production efficiency, dependable suppliers, safe transport conditions, and quality-focused production practices also play a major role in shaping its global demand.
Raw Material for Gadoteridol Production
According to the Gadoteridol production plant project report, the major raw materials for Gadoteridol production include 10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (HP-DO3A)- Gadolinium(III) salts (commonly gadolinium chloride or gadolinium oxide).
Production Process of Gadoteridol
The extensive Gadoteridol production cost report consists of the following industrial production processes:
- Production from a Macrocyclic ligand component: The production process of Gadoteridol begins with preparing the macrocyclic ligand known as 10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (HP-DO3A), which is built through a series of controlled reactions. These reactions shape the ring structure and attach the needed side groups. These steps are carried out at a particular temperature and pH so the ligand forms correctly and unwanted isomers stay low. After the ligand is purified, it is combined with a gadolinium salt under carefully adjusted conditions to allow the metal to be fully captured inside the macrocycle. Once the complex has formed, the mixture goes through purification stages such as crystallization, chromatography, or ultrafiltration to remove leftover ligand, traces of free gadolinium, and other byproducts. Then, the purified material is isolated and dried to obtain high-quality form of Gadoteridol as the final product.
Gadoteridol exists in the form of a white, odourless solid that dissolves easily in water. The density of the solid is about 1.30 g/cm³. It forms stable, non-ionic solutions and is supplied mainly in aqueous form for medical use. The molecular formula of the compound is C17H29GdN4O7 and its molar mass is 558.70 g/mol. It does not have a clear melting point because the compound breaks down when heated. It also has no practical boiling point or flash point due to its non-volatile nature. Long exposure to gadolinium-based materials can pose risks for individuals with impaired kidney function, so utmost care is advised while working with the compound. It is recommended to wear gloves and eye protection when handling the compound, and direct contact with the dry compound should be avoided.